Thorvardur Halfdanarson

Professor of Oncology

Mayo Clinic

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thorvardur Halfdanarson is a Professor of Oncology at Mayo Clinic in the United States. His research focuses on neuroendocrine tumors, particularly concerning treatment management, clinical outcomes, and molecular profiling. Recent articles explore topics such as the role of PRRT in advanced GEP-NET treatment and the risk associated with therapy-related myeloid neoplasms. He also investigates biomarkers and surgical management in pancreatic neuroendocrine tumors and acinar cell carcinoma.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (7)

Brian Burkett

Assistant Professor

Mayo Clinic

UNITED STATES

View details

Seung-Mo Hong

Professor

Asan Medical Center

SOUTH KOREA

View details

Simona Grozinsky-Glasberg

ISRAEL

View details

Amit Mahipal

University Hospitals Seidman Cancer Center

UNITED STATES

View details

Jun Yin

Assistant Professor

Mayo Clinic Minnesota

UNITED STATES

View details

Lewis Roberts

Professor

Mayo Clinic College of Medicine and Science

UNITED STATES

View details

Mukesh Pandey

Professor of Radiology

Mayo Clinic

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thorvardur Halfdanarson

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT

Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?

Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective

Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma

Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study

Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma

Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary

The feasibility and outcomes of metabolic and bariatric surgery prior to neoplastic therapy

Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study

Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study

Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States

Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies

Targeted Alpha-Particle Therapy: A Review of Current Trials

DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition

A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

Interventional vs surgical procedures in localized/nonmetastatic insulinomas (ablation vs surgery)

COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

Deep and Repeated Response to Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2–Amplified Large-Cell Neuroendocrine Carcinoma With Brain Metastases: A Case Report

N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma

Collaborators (7)

Brian Burkett

Seung-Mo Hong

Simona Grozinsky-Glasberg

Amit Mahipal

Jun Yin

Lewis Roberts

Mukesh Pandey

Make your next move.